FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898020169> ?p ?o ?g. }

• W2898020169 abstract "The Orphan Drug Act was enacted in 1983 to encourage the development of drugs for rare diseases. Previous research has attempted to examine the impact of the Act by assessing either the number of orphan designations that have been granted or the number of new orphan drugs approved for marketing. This study provides a more in-depth understanding of the effect of the Orphan Drug Act by investigating all types of drug approvals with an orphan designation, along with multiple characteristics of the drugs, over the entire 35 years of the Act. These orphan approvals include: new molecular entities (new drugs approved first for a rare disease), secondary indications (an expansion from the first approved indication), and new formulations. The results show that the number of approvals for orphan indications has been increasing over time, and the upward trend is especially large in the most recent years. Much of this increase has been driven by the increase in secondary indications being approved for previously approved drugs, although there have also been increases in the number of approved new drugs. We also find that while oncology indications have been increasing significantly, there has also been an increase in other therapeutic areas. Additionally, we find that the proportion of biologic drugs being approved has increased over time. Lastly, while other parts of this drug landscape have dramatically altered over time, the proportion of orphan approvals receiving priority review has not changed. Our data suggest that the Orphan Drug Act appears to have stimulated significant drug development for rare diseases. Additionally, approvals of orphan indications have been increasing over time. This increasing effect has not targeted a single area of the rare disease space, rather, gains in approvals have been seen across: therapeutic areas, approval types (both new drugs and secondary indications), and for both biologics and small molecule drugs." @default.
• W2898020169 created "2018-10-26" @default.
• W2898020169 creator A5052998210 @default.
• W2898020169 creator A5053849238 @default.
• W2898020169 date "2018-10-22" @default.
• W2898020169 modified "2023-10-14" @default.
• W2898020169 title "Investigating the landscape of US orphan product approvals" @default.
• W2898020169 cites W2019375534 @default.
• W2898020169 cites W2024559544 @default.
• W2898020169 cites W2025971693 @default.
• W2898020169 cites W2035802792 @default.
• W2898020169 cites W2036132972 @default.
• W2898020169 cites W2054519060 @default.
• W2898020169 cites W2059992865 @default.
• W2898020169 cites W2104505549 @default.
• W2898020169 cites W2118820600 @default.
• W2898020169 cites W2123407823 @default.
• W2898020169 cites W2294423247 @default.
• W2898020169 cites W2571094594 @default.
• W2898020169 cites W2770849724 @default.
• W2898020169 doi "https://doi.org/10.1186/s13023-018-0930-3" @default.
• W2898020169 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6198498" @default.
• W2898020169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30348193" @default.
• W2898020169 hasPublicationYear "2018" @default.
• W2898020169 type Work @default.
• W2898020169 sameAs 2898020169 @default.
• W2898020169 citedByCount "34" @default.
• W2898020169 countsByYear W28980201692019 @default.
• W2898020169 countsByYear W28980201692020 @default.
• W2898020169 countsByYear W28980201692021 @default.
• W2898020169 countsByYear W28980201692022 @default.
• W2898020169 countsByYear W28980201692023 @default.
• W2898020169 crossrefType "journal-article" @default.
• W2898020169 hasAuthorship W2898020169A5052998210 @default.
• W2898020169 hasAuthorship W2898020169A5053849238 @default.
• W2898020169 hasBestOaLocation W28980201691 @default.
• W2898020169 hasConcept C126322002 @default.
• W2898020169 hasConcept C2779134260 @default.
• W2898020169 hasConcept C2779701055 @default.
• W2898020169 hasConcept C2780035454 @default.
• W2898020169 hasConcept C2992293740 @default.
• W2898020169 hasConcept C60644358 @default.
• W2898020169 hasConcept C71924100 @default.
• W2898020169 hasConcept C75480439 @default.
• W2898020169 hasConcept C86803240 @default.
• W2898020169 hasConcept C98274493 @default.
• W2898020169 hasConceptScore W2898020169C126322002 @default.
• W2898020169 hasConceptScore W2898020169C2779134260 @default.
• W2898020169 hasConceptScore W2898020169C2779701055 @default.
• W2898020169 hasConceptScore W2898020169C2780035454 @default.
• W2898020169 hasConceptScore W2898020169C2992293740 @default.
• W2898020169 hasConceptScore W2898020169C60644358 @default.
• W2898020169 hasConceptScore W2898020169C71924100 @default.
• W2898020169 hasConceptScore W2898020169C75480439 @default.
• W2898020169 hasConceptScore W2898020169C86803240 @default.
• W2898020169 hasConceptScore W2898020169C98274493 @default.
• W2898020169 hasIssue "1" @default.
• W2898020169 hasLocation W28980201691 @default.
• W2898020169 hasLocation W28980201692 @default.
• W2898020169 hasLocation W28980201693 @default.
• W2898020169 hasLocation W28980201694 @default.
• W2898020169 hasOpenAccess W2898020169 @default.
• W2898020169 hasPrimaryLocation W28980201691 @default.
• W2898020169 hasRelatedWork W1987255708 @default.
• W2898020169 hasRelatedWork W2024559544 @default.
• W2898020169 hasRelatedWork W2035802792 @default.
• W2898020169 hasRelatedWork W2124846732 @default.
• W2898020169 hasRelatedWork W2898020169 @default.
• W2898020169 hasRelatedWork W2941820031 @default.
• W2898020169 hasRelatedWork W3198599987 @default.
• W2898020169 hasRelatedWork W3213446404 @default.
• W2898020169 hasRelatedWork W4282958968 @default.
• W2898020169 hasRelatedWork W4293476638 @default.
• W2898020169 hasVolume "13" @default.
• W2898020169 isParatext "false" @default.
• W2898020169 isRetracted "false" @default.
• W2898020169 magId "2898020169" @default.
• W2898020169 workType "article" @default.